Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to provide long-term CDZ173 treatment, a selective PI3Kδ inhibitor, to
the patients with genetically activated PI3Kδ, i.e., patients with APDS/PASLI who
participated in the CCDZ173X2201 study or who were treated previously with PI3Kδ inhibitors
other than CDZ173. The study is open-label designed to establish the long-term safety,
tolerability, efficay and pharmacokinetics of CDZ173 in the target population.